Home > Haematology > ASH 2020 > Multiple Myeloma > Survival of transplant-eligible newly diagnosed MM in FORTE trial

Survival of transplant-eligible newly diagnosed MM in FORTE trial

Presented By
Dr Francesca Gay, GIMEMA, European Myeloma Network, Italy
Conference
ASH 2020
Trial
Phase 2, FORTE
Lenalidomide alone is a standard maintenance treatment after an autologous stem cell transplantation (autoSCT). The phase 2 FORTE trial demonstrated that the addition of carfilzomib to lenalidomide maintenance improved progression-free survival (PFS) in patients with transplant-eligible newly diagnosed multiple myeloma (MM). The FORTE trial (NCT02203643) investigated safety and efficacy of the proteasome inhibitor carfilzomib in combination with either lenalidomide-dexamethasone (KRd) or cyclophosphamide-dexamethasone (KCd) in induction and consolidation of MM [1]. Secondary aim of the study was to evaluate maintenance treatment between carfilzomib plus lenalidomide or versus lenalidomide alone. The trial enrolled 474 MM patients who were transplant-eligible and aged <65 years. They were randomised in the following induction an...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on